Having shown that the Hsp90 inhibitor 17-DMAG decreases SARS-CoV-2 replication and associated pyroptosis in vitro, we wanted to determine whether it would be effective as a COVID-19 treatment in vivo. The gene discussed is HSP90AA1; the disease is COVID-19.